Tempus xT® CDx
Tumor-Normal Paired Sequencing
Comprehensive Genomic Profiling Comparing Tumor and Matched Normal DNA
Tempus xT CDx isn't just sequencing tumor DNA.
It compares tumor DNA to normal DNA.
Tempus AI's xT CDx uses NGS-based comprehensive genomic profiling (CGP) with tumor-normal paired sequencing. Instead of analyzing tumor DNA in isolation, it sequences both tumor and matched normal samples to distinguish somatic mutations from germline variants.
What the Test Measures
Tumor-Normal Paired Sequencing
- Sequencing of both tumor and matched normal DNA
- Enables differentiation between somatic mutations and germline variants
- Provides higher specificity for identifying clinically relevant alterations
DNA Alterations
- 648 cancer genes evaluated
- Detects single nucleotide variants (SNVs), insertions/deletions (indels), and copy number alterations
- Broad genomic coverage across key oncogenic pathways
Genomic Signatures
- MSI (Microsatellite Instability)
Why This Matters
These biomarkers support FDA-approved therapy–biomarker associations in colorectal cancer, including KRAS and NRAS, helping guide targeted treatment decisions.
Tumor-only sequencing can blur the distinction between inherited and acquired variants. Tumor-normal pairing provides critical context—improving specificity and enabling more confident interpretation.
How Casandra Structures This
At Casandra.ai, we separate what a test measures from what it reports—capturing both the structure of the assay and the clinical output.
Some genomic tests analyze tumor DNA alone. Others compare tumor to matched normal samples. Some analyze blood, while others rely on tissue.
Understanding these differences is essential to selecting the right test and interpreting results appropriately.